Filtros de búsqueda

Lista de obras de Enriqueta Felip

31Phosphorus magnetic resonance spectroscopy in the assessment of head and neck tumors

artículo científico publicado en 1998

5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging

scientific article published on 24 November 2018

A Phase Ib, Dose-Finding Study of Erlotinib in Combination With a Fixed Dose of Pertuzumab in Patients With Advanced Non–Small-Cell Lung Cancer

artículo científico publicado en 2012

A consensus statement on the gender perspective in lung cancer.

artículo científico publicado en 2016

A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers.

artículo científico publicado en 1999

A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy

artículo científico publicado en 2008

A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.

artículo científico

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

scientific article published on 22 July 2019

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

artículo científico publicado en 2015

A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).

artículo científico publicado en 2016

A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.

artículo científico publicado en 2017

A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer

artículo científico publicado en 1997

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer

scientific article published on 20 March 2019

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

artículo científico publicado en 2015

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

artículo científico publicado en 2015

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

artículo científico publicado en 2016

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation

artículo científico publicado en 2018

Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial

artículo científico publicado en 2014

Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms

artículo científico publicado en 2011

Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments

artículo científico

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol

scientific article published on 04 January 2019

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)

scientific article published on 27 February 2019

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

artículo científico

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

scientific article published on 14 August 2019

An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer

artículo científico publicado en 2013

Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

artículo científico publicado en 2016

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

artículo científico publicado en 2015

Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial

artículo científico publicado en 2013

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study

artículo científico publicado en 2019

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

artículo científico

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

artículo científico publicado en 2018

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

artículo científico publicado en 2015

BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL.

artículo científico publicado en 2014

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

artículo científico publicado en 2004

Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

artículo científico publicado en 2014

Bone metastases with nerve root compression as a late complication in patient with epithelial pleural mesothelioma

artículo científico publicado en 2013

Brain metastases: the need for a more tailored approach in non-small-cell lung cancer patients ⬇️

artículo científico publicado el 1 de enero de 2012

Brief Report: Phase 2 Study of the HSP-90 inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

artículo científico publicado en 2017

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer

scientific article published on 25 September 2018

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two Phase II trials.

artículo científico publicado en 2017

COX-2 inhibitors in NSCLC: never-ending story or misplaced?

artículo científico publicado en 2018

Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?

artículo científico publicado en 2012

Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up.

artículo científico publicado en 2008

Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up.

artículo científico publicado en 2009

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

artículo científico publicado en 2015

Ceritinib in ALK-rearranged non-small-cell lung cancer

artículo científico publicado en 2014

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

artículo científico publicado en 2017

Cisplatin and Vinorelbine Followed by Radiotherapy in the Treatment of Stage III-B Non-Small-Cell Lung Cancer Patients ⬇️

artículo científico publicado el 1 de agosto de 1997

Clinical Management of Adverse Events Associated with Lorlatinib

scientific article published on 19 March 2019

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

artículo científico publicado en 2013

Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery

artículo científico publicado en 2005

Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib

artículo científico publicado en 2009

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

scientific article published on 30 May 2019

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

scientific article published on 01 February 2019

Combined Chemotherapy, Radiotherapy and Surgery in Inflammatory Breast Carcinoma

scientific article published on 01 January 1995

Computed tomography (CT) predicts accurately the pathologic tumour size in stage I non-small-cell lung cancer (NSCLC).

scientific article published on December 2010

Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

artículo científico publicado en 2019

Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75].

artículo científico publicado en 2018

Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations

artículo científico publicado en 2005

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

artículo científico publicado en 2018

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

artículo científico publicado en 2007

DNA repair protein expression in resected NSCLC: a different predictive value for platinum benefit in adenocarcinoma versus squamous-cell carcinoma?

artículo científico publicado en 2012

Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions

artículo científico publicado en 1999

Differentiating between malignant and idiopathic pleural effusions: the value of diagnostic procedures.

artículo científico publicado en 2007

Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer

artículo científico publicado en 2011

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).

artículo científico publicado en 2017

Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection

scientific article published on 08 May 2019

ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity

artículo científico publicado en 2015

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

artículo científico publicado en 2016

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)

artículo científico publicado en 2005

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC)

artículo científico publicado en 2005

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

artículo científico publicado en 2013

Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2010

Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.

artículo científico publicado en 2016

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.

artículo científico publicado en 2017

Emerging drugs for non-small-cell lung cancer

artículo científico publicado en 2007

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

artículo científico publicado en 2017

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

artículo científico publicado en 2012

Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]

scientific article published on 01 December 2019

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

artículo científico publicado en 2017

Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.

artículo científico publicado en 2013

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014.

artículo científico publicado en 2018

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

artículo científico publicado en 2017

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

artículo científico publicado en 2014

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

scientific article published on 02 June 2019

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients

artículo científico publicado en 2013

Ganitumab for the treatment of small-cell lung cancer

artículo científico

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery

artículo científico publicado en 2004

Genetic testing for chemotherapy in non-small cell lung cancer

artículo científico publicado en 2003

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

artículo científico publicado en 2017

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

artículo científico publicado en 2014

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity

artículo científico publicado en 2013

Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).

artículo científico publicado en 2012

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

artículo científico publicado en 2013

HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?

artículo científico publicado en 2018

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC

scientific article published on 31 January 2019

How could pharmacogenomics help improve patient survival?

artículo científico publicado en 2007

How to integrate current knowledge in selecting patients for first line in NSCLC? ⬇️

artículo científico publicado el 1 de octubre de 2010

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.

artículo científico publicado en 2017

Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.

artículo científico publicado en 2017

Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology

artículo científico publicado en 2016

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors

scientific article published on 06 February 2019

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

artículo científico publicado en 2016

Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.

artículo científico publicado en 1994

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

scientific article published on 06 November 2018

Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07.

artículo científico publicado en 2017

Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07.

artículo científico publicado en 2016

Lung cancer in Spanish women: The WORLD07 project

article

Lung cancer in women: an overview with special focus on Spanish women

artículo científico publicado en 2013

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

artículo científico publicado en 2013

Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters

MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3: Topic: Medical Oncology

artículo científico publicado en 2016

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2010

Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

artículo científico publicado en 2008

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.

artículo científico publicado en 2014

Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists.

artículo científico publicado en 2017

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2012

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

artículo científico publicado en 2010

Molecular predictors of response to chemotherapy in lung cancer

artículo científico publicado en 2004

Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?

artículo científico publicado en 2014

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

artículo científico publicado en 2018

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

artículo científico publicado en 2016

Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2012

Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2010

Nasopharyngeal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

artículo científico publicado en 2008

Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development

artículo científico publicado en 2011

Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer

artículo científico publicado en 2002

Neoadjuvant chemotherapy in early-stage non-small cell lung cancer

Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer

artículo científico publicado en 2012

New anti-tubulin agents.

artículo científico publicado en 2002

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

artículo científico publicado en 2017

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

artículo científico publicado en 2015

Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

artículo científico publicado en 2018

Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

scientific article published on 01 May 2008

Novel approaches in the treatment of non-small-cell lung cancer.

artículo científico publicado en 2001

ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology

artículo científico publicado en 2016

Orbital Metastases from Transitional-Cell Cancer of the Urinary Bladder

artículo científico publicado en 1991

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

artículo científico publicado en 2016

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.

artículo científico publicado en 2018

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

artículo científico publicado en 2017

Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

scientific article published in Nature Communications

Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

artículo científico publicado en 1995

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis

P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy

artículo científico publicado en 2016

P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy

artículo científico

PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment

artículo científico

PI3K Pathway in NSCLC

artículo científico publicado en 2011

PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC

PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology

artículo científico publicado en 2016

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

artículo científico publicado en 2017

Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?

artículo científico publicado en 2017

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

scientific article published on 12 March 2019

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

artículo científico publicado en 2018

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

artículo científico publicado en 2015

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

artículo científico publicado en 2008

Pemetrexed in previously treated non-small-cell lung cancer.

artículo científico publicado en 2004

Personalizing therapy with targeted agents in non-small cell lung cancer

artículo científico publicado en 2011

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2005

Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.

artículo científico publicado en 2014

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

artículo científico publicado en 2013

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

artículo científico publicado en 2017

Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer

artículo científico publicado en 2010

Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.

artículo científico publicado en 2001

Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer.

artículo científico publicado en 2005

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

artículo científico publicado en 2016

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

artículo científico publicado en 2005

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC.

artículo científico publicado en 2015

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

artículo científico publicado en 2017

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer

artículo científico publicado en 2018

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

artículo científico publicado en 2019

Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer.

artículo científico publicado en 2001

Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer

artículo científico publicado en 2010

Preoperative High-Dose Cisplatin Versus Moderate- Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial

artículo científico publicado en 2000

Preoperative Simultaneous Chemoradiotherapy in Locally Advanced Cancer of the Oral Cavity and Oropharynx

artículo científico publicado en 1997

Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project

artículo científico publicado en 2017

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

scientific article published on 31 January 2019

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

artículo científico publicado en 2019

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer

scientific article published on 11 April 2019

Rectal Metastases from Squamous Cell Carcinoma: A Case Report and Review of the Literature ⬇️

artículo científico publicado el 10 de abril de 2012

Role of multimodality treatment for lung cancer.

artículo científico publicado en 2000

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013.

artículo científico publicado en 2013

SEOM guidelines for the management of non-small-cell lung cancer (NSCLC)

artículo científico publicado en 2009

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

artículo científico publicado en 2015

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

scientific article published on 09 April 2019

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study

scientific article published on 01 August 2018

Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).

artículo científico publicado en 2012

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

scientific article published on 08 July 2019

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial

scientific article published on 03 May 2019

Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study ⬇️

artículo científico publicado el 1 de octubre de 2003

Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non–Small-Cell Lung Cancer (NSCLC)

artículo científico publicado en 2011

Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine

artículo científico publicado en 2011

Single-cell transcriptome conservation in cryopreserved cells and tissues

artículo científico publicado en 2017

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

artículo científico publicado en 2013

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

artículo científico publicado en 2010

Small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

artículo científico publicado en 2008

Small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

artículo científico publicado en 2007

Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

artículo científico publicado en 2010

Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

artículo científico publicado en 2008

Strategies for improving outcomes in NSCLC: a look to the future

artículo científico

Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study

artículo científico publicado en 2010

Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.

artículo científico publicado en 1998

Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer

artículo científico publicado en 2008

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

artículo científico publicado en 2016

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

artículo científico publicado en 2015

TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial.

artículo científico publicado en 2015

Targeted therapies development in the treatment of advanced nonsmall cell lung cancer

artículo científico publicado en 2011

Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response

artículo científico publicado en 2007

The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

artículo científico publicado en 2016

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

artículo científico publicado en 2016

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy

artículo científico publicado en 2017

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

artículo científico publicado en 2014

The role of chemotherapy in early non-small-cell lung cancer management.

artículo científico publicado en 2001

Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe: Table 1–

artículo científico publicado en 2013

Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology.

scientific article published on September 2016

Tissue sampling in lung cancer: a review in light of the MERIT experience

artículo científico publicado en 2011

Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting

artículo científico publicado en 2011

Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

artículo científico

Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going

artículo científico publicado en 2006

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus

artículo científico publicado en 2019

Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors.

artículo científico publicado en 2014

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

artículo científico publicado en 2019

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

scientific article published on 01 February 2019

Usefulness of predictive tests for cancer treatment.

artículo científico publicado en 2006

Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial

artículo científico publicado en 2014

Women in oncology: progress, challenges, and keys to success

artículo científico publicado en 2013

World Conference on Lung Cancer

artículo científico publicado en 2003

YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib

artículo científico publicado en 2019

[C-erbB-2 protein in ovarian epithelial cancer: correlation between expression in tumor tissue and blood levels]

scientific article published on 01 June 1995

[Nuclear magnetic resonance in mediastinal pathology]

artículo científico publicado en 1990

[Treatment response and long term survival of a patient seropositive for the human immunodeficiency virus with non-Hodgkin's lymphoma]

artículo científico publicado en 1994

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda